Direxion Daily S&P Biotech Bull 3X ETF Rating $210.02 -0.76 (-0.36%) Closing price 04:10 PM EasternExtended Trading$209.50 -0.52 (-0.25%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Direxion Daily S&P Biotech Bull 3X ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy 2.63Holdings in LABU have an aggregate rating of Moderate Buy based on 339 analyst ratings issued in the past year covering 16 companies (20.0% of the portfolio).LABU Aggregate Price Target$210.02High Prediction$210.02Average Prediction$210.02Low Prediction$210.02Holdings in LABU have an aggregate price target of $210.02 and a range of $210.02 to $210.02 covering 16 companies (20.0% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3X ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 16 LABU Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings1.72%TWSTTwist Bioscience$148.16-2.1%Hold$143.67 -3.0%131.9549 of 5 starsAnalyst ForecastInsider TradeGap Down1.60%MRNAModerna$226.30+4.6%Hold$100.60 -55.5%261.7591 of 5 starsTrending News1.42%NTRANatera$394.75-0.2%Moderate Buy$368.69 -6.6%231.8681 of 5 starsAnalyst Forecast1.29%UTHRUnited Therapeutics$540.03-0.6%Moderate Buy$639.08 18.3%144.0621 of 5 starsTrending NewsAnalyst ForecastInsider Trade1.24%IOVAIovance Biotherapeutics$14.21-2.0%Moderate Buy$13.20 -7.1%132.0778 of 5 starsAnalyst Forecast1.21%BIIBBiogen$232.83+1.7%Moderate Buy$236.04 1.4%322.5273 of 5 starsAnalyst Upgrade1.19%AMGNAmgen$426.11+3.2%Hold$387.93 -9.0%303.7651 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision1.19%SYRESpyre Therapeutics$78.63-2.3%Moderate Buy$110.40 40.4%172.6298 of 5 starsAnalyst Upgrade1.19%ABBVAbbVie$283.58+3.4%Moderate Buy$277.18 -2.3%304.6008 of 5 starsTrending NewsAnalyst ForecastOptions VolumeAnalyst Revision1.17%CRSPCRISPR Therapeutics$50.22+0.2%Moderate Buy$67.50 34.4%193.4398 of 5 starsAnalyst Forecast1.16%GILDGilead Sciences$153.54+3.8%Moderate Buy$159.33 3.8%293.2073 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision1.14%HALOHalozyme Therapeutics$116.82+6.6%Moderate Buy$96.50 -17.4%123.4415 of 5 starsAnalyst Forecast1.14%EXELExelixis$60.99+2.5%Hold$50.79 -16.7%202.3041 of 5 starsAnalyst Revision1.14%RVMDRevolution Medicines$193.52+2.7%Moderate Buy$234.81 21.3%242.8291 of 5 starsAnalyst Forecast1.12%TGTXTG Therapeutics$54.37+0.1%Moderate Buy$63.00 15.9%93.5159 of 5 stars1.11%VRTXVertex Pharmaceuticals$498.50+2.7%Moderate Buy$579.81 16.3%284.066 of 5 stars This page (NYSEARCA:LABU) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3X ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3X ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
